Oral administration of mesalazine protects against mucosal injury and permeation in dextran sulfate sodium-induced colitis in rats

Scandinavian Journal of Gastroenterology

Volumn 44, Issue 11, 2009, Pages 1323-1331

  Hayashi, Yoshihiro ^a   Aoyagi, Kunihiko ^a   Morita, Isamu ^a   Yamamoto, Chifumi ^a   Sakisaka, Shotaro ^a  

^a FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Colonic mucosal permeation; Dextran sodium sulfate; Evans blue; Mesalazine; Rat; Tight junction

Indexed keywords

DEXTRAN SULFATE; EVANS BLUE; MESALAZINE; MYELOPEROXIDASE; OCCLUDIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLON MUCOSA; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; DISEASE MODEL; ENZYME ACTIVITY; HISTOPATHOLOGY; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; INTESTINE INJURY; INTESTINE MUCOSA PERMEABILITY; LEUKOCYTE COUNT; MALE; NONHUMAN; ORGAN SIZE; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN DETERMINATION; PROTEIN LOCALIZATION; RAT; SCORING SYSTEM; TISSUE DISTRIBUTION; ULCERATIVE COLITIS;

ADMINISTRATION, ORAL; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLITIS; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; INTESTINAL MUCOSA; MALE; MESALAMINE; PERMEABILITY; RATS; RATS, WISTAR; TREATMENT OUTCOME;

EID: 70449515893     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365520903262414     Document Type: Article

References (46)

1. Azad Khan AK, Piris J, Truelove SC. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet 1977;2:892-895
2. Baumgart DC, Vierziger K, Sturm A, Wiedenmann B, Dignass AU. Mesalamine promotes intestinal epithelial wound healing in vitro through a TGF-beta-independent mechanism. Scand J Gastroenterol 2005;40:958-964
3. Rumi G, Tsubouchi R, Okayama M, Kato S, Mozsik G, Takeuchi K. Protective effect of lactulose on dextran sulfate sodium-induced colonic inflammation in rats. Dig Dis Sci 2004;49:1466-1472 (Pubitemid 39273624)
4. Kimura I, Kawasaki M, Nagahama S, Matsuda A, Kataoka M, Kokuba Y. Determination of the active moietyof BX661A, a new therapeutic agent for ulcerative colitis, by studying its therapeutic effects on ulcerative colitis induced by dextran sulfate sodium in rats. Arzneimittelforschung 1998;48:1091-1096
5. Rijk MC, van Schaik A, van Tongeren JH. Disposition of 5-aminosalicylic acid by 5-aminosalicylic acid-delivering compounds. Scand J Gastroenterol 1988;23:107-112 (Pubitemid 18067038)
6. Safdi AV, Cohen RD. Review article: increasing the dose of oral mesalazine therapy for active ulcerative colitis does not improve remission rates. Aliment Pharmacol Ther 2007; 26:1179-1186
7. Kucharzik T, Walsh SV, Chen J, Parkos CA, Nusrat A. Neutrophil transmigration in inflammatory bowel disease is associated with differential expression of epithelial intercellular junction proteins. Am J Pathol 2001;159:2001-2009
8. Tsukita S, Furuse M. Overcoming barriers in the study of tight junction functions: from occludin to claudin. Genes Cells 1998;3:569-573
9. Stevenson BR, Siliciano JD, Mooseker MS, Goodenough DA. Identification of ZO-1: a high molecular weight polypeptide associated with the tight junction (zonula occludens) in a variety of epithelia. J Cell Biol 1986;103:755-766
10. Fries W, Mazzon E, Squarzoni S, Martin A, Martines D, Micali A, et al. Experimental colitis increases small intestine permeability in the rat. Lab Invest 1999;79:49-57.
11. Kitajima S, Takuma S, Morimoto M. Changes in colonic mucosal permeability in mouse colitis induced with dextran sulfate sodium. Exp Anim 1999;48:137-143
12. Poritz LS, Garver KI, Green C, Fitzpatrick L, Ruggiero F, Koltun WA. Loss of the tight junction protein ZO-1 in dextran sulfate sodium induced colitis. J Surg Res 2007; 140:12-19.
13. Cooper HS, Murthy SN, Shah RS, Sedergran DJ. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest 1993;69:238-249
14. Krawisz JE, Sharon P, Stenson WF. Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models. Gastroenterology 1984;87:1344-1350
15. Lange S, Delbro DS, Jennische E. Evans blue permeation of intestinal mucosa in the rat. Scand J Gastroenterol 1994; 29:38-46.
16. Suzuki N, Irie M, Iwata K, Nakane H, Yoshikane M, Koyama Y, et al. Altered expression of alkaline phosphatase (ALP) in the liver of primary biliary cirrhosis (PBC) patients. Hepatol Res 2006;35:37-44.
17. Maxton DG, Bjarnason I, Reynolds AP, Catt SD, Peters TJ, Menzies IS. Lactulose, 51Cr-labelled ethylenediaminetetra- acetate, L-rhamnose and polyethyleneglycol 400 [corrected] as probe markers for assessment in vivo of human intestinal permeability. Clin Sci (Lond) 1986;71:71-80.
18. Fleming SC, Kapembwa MS, Laker MF, Levin GE, Griffin GE. Rapid and simultaneous determination of lactulose and mannitol in urine, by HPLC with pulsed amperometric detection, for use in studies of intestinal permeability. Clin Chem 1990;36:797-799
19. Bjarnason I. Intestinal permeability. Gut 1994;35:S18-22.
20. Singh AB, Harris RC. Epidermal growth factor receptor activation differentially regulates claudin expression and enhances transepithelial resistance in Madin-Darby canine kidney cells. J Biol Chem 2004;279:3543-3552
21. Naftalin RJ, Zammit PS, Pedley KC. Regional differences in rat large intestinal crypt function in relation to dehydrating capacity in vivo. J Physiol 1999;514:201-210
22. Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y, Nakaya R. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 1990;98:694-702.
23. von Ritter C, Grisham MB, Granger DN. Sulfasalazine metabolites and dapsone attenuate formyl-methionylleucyl- phenylalanine-induced mucosal injury in rat ileum. Gastroenterology 1989;96:811-816
24. Sartor RB, Anderle SK, Rifai N, Goo DA, Cromartie WJ, Schwab JH. Protracted anemia associated with chronic, relapsing systemic inflammation induced by arthropathic peptidoglycan-polysaccharide polymers in rats. Infect Immun 1989;57:1177-1185
25. Powell DW. Barrier function of epithelia. Am J Physiol 1981;241:G275-88.
26. Schneeberger EE, Lynch RD. Structure, function, and regulation of cellular tight junctions. Am J Physiol 1992;262: L647-61.
27. Hollander D. The intestinal permeability barrier. A hypothesis as to its regulation and involvement in Crohn's disease. Scand J Gastroenterol 1992;27:721-726
28. Juuti-Uusitalo K, Lindfors K, Maki M, Patrikainen M, Isola J, Kaukinen K. Inhibition of epithelial growth factor receptor signalling does not preserve epithelial barrier function after in vitro gliadin insult. Scand J Gastroenterol 2009;15:1-6.
29. Balda MS, Matter K. Tight junctions. J Cell Sci 1998; 111:541-547
30. Denker BM, Nigam SK. Molecular structure and assembly of the tight junction. Am J Physiol 1998;274:F1-9.
31. Sakisaka S, Kawaguchi T, Taniguchi E, Hanada S, Sasatomi K, Koga H, et al. Alterations in tight junctions differ between primary biliary cirrhosis and primary sclerosing cholangitis. Hepatology 2001;33:1460-1468
32. Sawada N, Murata M, Kikuchi K, Osanai M, Tobioka H, Kojima T, et al. Tight junctions and human diseases. Med Electron Microsc 2003;36:147-156
33. Fanning AS, Jameson BJ, Jesaitis LA, Anderson JM. The tight junction protein ZO-1 establishes a link between the transmembrane protein occludin and the actin cytoskeleton. J Biol Chem 1998;273:29745-29753
34. Itoh M, Furuse M, Morita K, Kubota K, Saitou M, Tsukita S. Direct binding of three tight junction-associated MAGUKs, ZO-1, ZO-2, and ZO-3, with the COOH termini of claudins. J Cell Biol 1999;147:1351-1363
35. Tsukita S, Furuse M. Occludin and claudins in tight-junction strands: leading or supporting players? Trends Cell Biol 1999;9:268-273
36. Furuse M, Hirase T, Itoh M, Nagafuchi A, Yonemura S, Tsukita S, et al. Occludin: a novel integral membrane protein localizing at tight junctions. J Cell Biol 1993; 123:1777-1788
37. Mazzon E, Sturniolo GC, Puzzolo D, Frisina N, Fries W. Effect of stress on the paracellular barrier in the rat ileum. Gut 2002;51:507-513
38. Sharon P, Ligumsky M, Rachmilewitz D, Zor U. Role of prostaglandins in ulcerative colitis. Enhanced production during active disease and inhibition by sulfasalazine. Gastroenterology 1978;75:638-640
39. Kaiser GC, Yan F, Polk DB. Mesalamine blocks tumor necrosis factor growth inhibition and nuclear factor kappaB activation in mouse colonocytes. Gastroenterology 1999; 116:602-609
40. Subramanian S, Rhodes JM, Hart CA, Tam B, Roberts CL, Smith SL, et al. Characterization of epithelial IL-8 responseto inflammatory bowel disease mucosal E. coli and its inhibition by mesalamine. Inflamm Bowel Dis 2008; 14:162-175
41. Rousseaux C, Lefebvre B, Dubuquoy L, Lefebvre P, Romano O, Auwerx J, et al. Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma. J Exp Med 2005; 201:1205-1215
42. Moeser AJ, Haskell MM, Shifflett DE, Little D, Schultz BD, Blikslager AT. ClC-2 chloride secretion mediates prostaglandin- induced recovery of barrier function in ischemia-injured porcine ileum. Gastroenterology 2004;127:802-805
43. Otte JM, Podolsky DK. Functional modulation of enterocytes by gram-positive and gram-negative microorganisms. Am J Physiol Gastrointest Liver Physiol 2004;286: G613-26.
44. Ponferrada A, Caso JR, Alou L, Colón A, Sevillano D, Moro MA, et al. The role of PPARgamma on restoration of colonic homeostasis after experimental stress-induced inflammation and dysfunction. Gastroenterology. 2007;132:1791-1803
45. Han X, Ren X, Jurickova I, Groschwitz K, Pasternak BA, Xu H, et al. Regulation of intestinal barrier function by signal transducer and activator of transcription 5b. Gut 2009; 58:49-58.
46. Sakisaka S, Koga H, Sasatomi K,Mimura Y, Kawaguchi T, Tanikawa K. Biliary secretion of endotoxin and pathogenesis of primary biliary cirrhosis. Yale J Biol Med 1997; 70:403-408 (Pubitemid 28262255)